The Latest Analyst Ratings for Kodiak Gas Services

Within the last quarter, Kodiak Gas Services (NYSE:KGS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…

Within the last quarter, Kodiak Gas Services (NYSE:KGS) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 4 1 0 0
Last 30D 0 1 0 0 0
1M Ago 3 3 1 0 0
2M Ago 0 0 0 0 0
3M Ago 0 0 0 0 0

In the last 3 months, 8 analysts have offered 12-month price targets for Kodiak Gas Services. The company has an average price target of $22.88 with a high of $25.00 and a low of $19.00.

Below is a summary of how these 8 analysts rated Kodiak Gas Services over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has increased by 8.95% from the previous average price target of $21.00.

Stay up to date on Kodiak Gas Services analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

What Are Analyst Ratings?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Monetization Opportunities Galore: Analyst Predicts Generative AI Will Grow Microsoft Stock

Despite a 1Q rally, software stocks remain challenged by macroeconomic pressures and high levels of uncertainty, with recent regional banking failures adding to collective anxiety levels, Mizuho analyst Gregg Moskowitz notes.  Net, many investors understandably remain cautious about increasing software exposure now. 

MSFT

Read More

What’s Going On With Crispr Therapeutics Stock?

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have risen nearly 37% over the past month following the FDA approval of Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older on Jan. 16.

CRSP